Saturday 17 October 2026 Export AKBA’s income statement to Excel — free account

Akebia Therapeutics, Inc.

AKBA Healthcare Drug Manufacturers Specialty & Generic

Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024. In the quarter to June 2026, revenue fell 21.4%, EPS fell 3,433.3%, free cash flow fell 89.0% and total debt rose 5.31%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.67 0.03 −4.29%

Follow AKBA

Alert me

Market cap: $192.7M
P/E: 0.0×
Fwd P/E: −6.3×
Dividend yield: —
F-score: 7/9
Altman Z: −4.42
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.09

Total sells 0.96

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	6	—	—	—	1	—	—	—	—

Insider Ownership 0.01%

Capital & Financial Ratios $m

Market Cap 192.73

Revenue 219.06

Net Income (29.67)

Free Cash Flow 40.26

Net Debt (105.98)

Current Ratio 1.43

Debt/Equity 1.98

P/E ratio 0.00

Fwd P/E (6.32)

P/S ratio 0.82

P/B ratio 7.22

Past 5Y EPS Growth —

This Y EPS Growth (600.58%)

Next Y EPS Growth (117.39%)

Next Y revenue growth (16.26%)

Next 5Y EPS Growth 55.04%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.25%

10-year low 10-year high

P/B against its own 10 years 71.76%

10-year low 10-year high

EV/Sales against its own 10 years 11.04%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	43	52	185	156
Receivables	39	34	47	54
Inventory	16	16	16	13
Other	—	—	—	—
	118	114	253	230

	2023	2024	2025	Q'26
Payables	15	15	21	9
ST’ Debt	18	—	—	25
Other	—	2	17	11
	100	81	163	161

Compound Annual Growth %

	10y	5y	3y
Sales	—	(4.33%)	(6.88%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(12.98%)	(33.33%)	84.06%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	54	49	—	—	—
’25	57	62	59	58	236
’24	33	44	37	46	160
’23	40	56	42	56	195
’22	62	126	49	56	292
’21	52	53	49	58	212
’20	88	90	60	56	295

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	4	—	—	—
’25	(14)	22	28	31	68
’24	(19)	(10)	(7)	(4)	(41)
’23	(18)	4	(7)	(2)	(23)
’22	(22)	(31)	34	(55)	(73)
’21	(71)	(63)	(56)	(63)	(253)
’20	(90)	37	(27)	(31)	(110)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	2	—	—	—
’25	(13)	22	28	31	68
’24	(19)	(10)	(7)	(4)	(41)
’23	(18)	4	(7)	(2)	(23)
’22	(22)	(31)	34	(55)	(73)
’21	(71)	(63)	(56)	(63)	(253)
’20	(90)	37	(27)	(31)	(111)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.03)	(0.03)	—	—	—
’25	0.03	0.00	0.00	(0.05)	(0.02)
’24	(0.09)	(0.04)	(0.10)	(0.10)	(0.33)
’23	(0.14)	(0.06)	(0.08)	0.00	(0.28)
’22	(0.35)	0.15	(0.28)	(0.04)	(0.51)
’21	(0.45)	(0.51)	(0.34)	(0.40)	(1.70)
’20	(0.47)	(1.28)	(0.42)	(0.60)	(2.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	7.00	8.58	5.20	2.99	2.09	2.20	0.24	0.49	0.80	1.45	Analyst estimates 2026–2028 Powerpack
	High	12.74	20.25	15.86	9.30	13.71	5.14	2.93	1.84	2.48	4.08
People
People	Employees	90	114	325	360	380	426	205	167	181	194
	Revenue/emp, $m	0.02	1.59	0.64	0.93	0.78	0.50	1.43	1.17	0.88	1.22
Income, $m
Income, $m	Revenue	2	181	208	335	295	212	292	195	160	236
	Gross margin, %	100.00	100.00	96.26	56.62	38.21	28.81	70.74	61.90	60.56	83.29
	EBT	(136)	(74)	(172)	(286)	(385)	(282)	(94)	(52)	(69)	(4)
	EBT margin, %	(8,843.45)	(40.65)	(82.76)	(85.46)	(130.61)	(133.25)	(32.22)	(26.68)	(43.33)	(1.58)
	Net income	(136)	(74)	(144)	(280)	(385)	(282)	(94)	(52)	(69)	(5)
	Depreciation	1	1	1	38	149	38	38	38	38	1
Per share, $
Per share, $	Revenue	0.04	4.17	3.58	2.83	2.13	1.28	1.60	1.04	0.76	0.92
	Earnings	(3.60)	(1.77)	(2.47)	(2.36)	(2.77)	(1.70)	(0.51)	(0.28)	(0.33)	(0.02)
	Cash flow	1.54	(1.29)	(1.68)	(2.17)	(0.80)	(1.52)	(0.40)	(0.12)	(0.19)	0.26
	Capex	(0.07)	(0.04)	(0.03)	(0.06)	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	1.46	(1.33)	(1.71)	(2.23)	(0.80)	(1.52)	(0.40)	(0.12)	(0.19)	0.26
	Book value	1.81	2.82	10.96	3.33	1.79	0.45	0.03	(0.16)	(0.23)	0.13
	Shares, m	38	44	58	118	138	166	183	187	211	257
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	3.59	1.54	2.23	1.32	1.77	0.39	1.22	2.50	1.75
	P/B	5.81	5.31	0.50	1.90	1.57	5.07	21.67	0.00	0.00	12.70
	EV/Sales	0.00	1.84	1.11	2.03	0.88	1.94	0.30	1.18	2.53	1.25
	EV/FCF	2.46	(5.77)	(2.33)	(2.58)	(2.30)	(1.62)	(1.21)	(9.78)	(9.96)	4.35
Cash, $m
Cash, $m	Operating cash flow	58	(56)	(97)	(257)	(110)	(253)	(73)	(23)	(41)	68
	Capex	(3)	(2)	(2)	(7)	0	0	0	—	0	0
	Free cash flow	55	(58)	(99)	(264)	(111)	(253)	(73)	(23)	(41)	68
Balance, $m
Balance, $m	Working capital	182	217	203	101	184	10	56	18	33	90
	Total debt	0	—	15	81	101	185	66	35	39	48
	Net debt	(260)	(318)	(90)	(67)	(127)	35	(24)	(8)	(13)	(137)
	Shareholders’ equity	68	123	636	395	248	74	5	(31)	(49)	33
Returns, %
Returns, %	ROA	(61.26)	(22.17)	(21.10)	(31.64)	(54.38)	(48.07)	(21.28)	(17.37)	(30.02)	(1.79)
	ROIC	0.00	0.00	(20.38)	(54.53)	(196.30)	(152.01)	0.00	0.00	0.00	0.00
	ROE	(136.35)	(77.27)	(37.86)	(54.27)	(119.82)	(175.37)	(237.83)	409.60	174.03	64.49

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ANIK Anika Therapeutics Inc.	$276.9M	— (loss-making)	— (loss-making)	+15.56% (above 0%: growing)	n/m	+61.58% (above 0%: growing)	65.15%	9.06%	Compare
ACB Aurora Cannabis Inc.	$265.8M	— (loss-making)	— (loss-making)	−31.15% (below 0%: shrinking)	n/m	−293.56% (below 0%: shrinking)	52.73%	(12.92%)	Compare
BIOA BioAge Labs, Inc.	$245.6M	— (loss-making)	— (loss-making)	+1.62% (above 0%: growing)	n/m	+2.68% (above 0%: growing)	100.00%	(1,196.78%)	Compare
LFCR Lifecore Biomedical, Inc.	$244.1M	— (loss-making)	— (loss-making)	−6.25% (below 0%: shrinking)	n/m	−117.03% (below 0%: shrinking)	35.34%	7.51%	Compare
SIGA Siga Technologies Inc.	$229.2M	— (loss-making)	28.7×	−49.45% (below 0%: shrinking)	−66.00% (below 0%: shrinking)	−75.95% (below 0%: shrinking)	57.17%	33.91%	Compare
AKBA Akebia Therapeutics, Inc.	$192.7M	— (loss-making)	— (loss-making)	−21.36% (below 0%: shrinking)	n/m	−88.99% (below 0%: shrinking)	78.78%	(12.88%)
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$236.7M	—	—	−6.25%	—	−36.63%	54.95%	1.23%

All 86 Drug Manufacturers Specialty & Generic stocks →

Akebia Therapeutics, Inc. (AKBA) key facts

Strength: Akebia Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $236.2 million, up 47.5% from fiscal 2024.
Akebia Therapeutics, Inc. (AKBA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AKBA traded at $0.67, a market capitalization of $192.7 million.
Return on equity was 64.5% and debt-to-equity 1.98.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is −4.42 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.